Strategic advancement of E3 ubiquitin ligase in the management of hepatocellular carcinoma
- 18 June 2024
- journal article
- review article
- Published by Springer Nature in Medical Oncology
- Vol. 41 (7) , 1-10
Abstract
Hepatocellular carcinoma (HCC) presents a significant global health challenge due to its high incidence, poor prognosis, and limited treatment options. As a pivotal regulator of protein stability, E3 ubiquitin ligase plays a crucial role in tumorigenesis and development. This review provides an overview of the latest research on the involvement of E3 ubiquitin ligase in hepatocellular carcinoma and elucidates its significance in hepatocellular carcinoma cell proliferation, invasion, and evasion from immune surveillance. Special attention is given to the functions of RING, HECT, and RBR E3 ubiquitin ligases and their association with hepatocellular carcinoma progression. By dissecting the molecular mechanisms and regulatory networks governed by E3 ubiquitin ligase, several potential therapeutic strategies are proposed: including the development of specific inhibitors targeting E3 ligases; augmentation of their tumor suppressor activity through drug or gene therapy; utilization of E3 ubiquitin ligase to modulate immune checkpoint proteins for improved efficacy of immunotherapy; combination strategies integrating traditional therapies with E3 ubiquitin ligase inhibitors; as well as biomarker development based on E3 ubiquitin ligase activity. Furthermore, this review discusses the prospect of overcoming drug resistance in hepatocellular carcinoma treatment through these novel approaches. Overall, this review establishes a theoretical foundation and offers fresh insights into harnessing the potential of E3 ubiquitin ligase for treating hepatocellular carcinoma while highlighting future research directions that pave the way for clinical translation studies and new drug discoveries.Keywords
Funding Information
- National Natural Science Foundation of China (82373034, 82203716)
- “13th Five-Year Plan” Science and Education Strong Health Project Innovation Team of Yangzhou (LJRC20181, YZCXTD201801)
- Provincial-level discipline leader of the NJPH (DTRA202214)
- Cross-cooperation special projects of the NJPH (YJCHZ-2021-08)
- Beijing iGandan Foundation (GDXZ-08-19)
- Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX22_3568, KYCX23_3617, SJCX23_2028)
This publication has 93 references indexed in Scilit:
- The Ubiquitin Ligase SCF(βTrCP) Regulates the Degradation of the Growth Hormone ReceptorJournal of Biological Chemistry, 2007
- The ring between ring fingers (RBR) protein familyGenome Biology, 2007
- Cell proliferation, apoptosis and the related regulators p27, p53 expression in hepatocellular carcinomaWorld Journal of Gastroenterology, 2005
- Parkin and relatives: the RBR family of ubiquitin ligasesPhysiological Genomics, 2004
- The p53–Mdm2 module and the ubiquitin systemSeminars in Cancer Biology, 2003
- Live or let die: the cell's response to p53Nature Reviews Cancer, 2002
- Mechanisms Underlying UbiquitinationAnnual Review of Biochemistry, 2001
- Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligaseOncogene, 2000
- Mdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53Journal of Biological Chemistry, 2000
- Cbl-b regulates the CD28 dependence of T-cell activationNature, 2000